Quick Takeaways
- Versant Venture Capital VI, L.P. filed SCHEDULE 13D/A for Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE).
- Disclosed ownership: 5.1%.
- Date of event: 10 Nov 2025.
Quoteable Key Fact
"Versant Venture Capital VI, L.P. disclosed 5.1% ownership in Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share (GLUE) on 10 Nov 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | 5.1% | 3,334,669 | 3,334,669 | 0 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P. | 0001687880 |
| Versant Ventures VI GP, L.P. | 5.1% | 3,334,669 | 0 | 3,334,669 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the General Partner of Versant Ventures VI GP, L.P. | 0001777654 |
| Versant Ventures VI GP-GP, LLC | 5.1% | 3,334,669 | 0 | 3,334,669 | /s/Max Eisenberg | Max Eisenberg/COO | 0001777652 |
| Versant Vantage I, L.P. | 2.4% | 1,573,453 | 1,573,453 | 0 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the GP of Versant Vantage I GP, L.P., the GP of Versant Vantage I, L.P. | |
| Versant Vantage I GP, L.P. | 2.4% | 1,573,453 | 0 | 1,573,453 | /s/Max Eisenberg | Max Eisenberg/COO of Versant Vantage I GP-GP, LLC, the General Partner of Versant Vantage I GP, L.P. | |
| Versant Vantage I GP-GP, LLC | 2.4% | 1,573,453 | 0 | 1,573,453 | /s/Max Eisenberg | Max Eisenberg/COO |